

## 1997 Cumulative Table of Contents Psychopharmacology Bulletin Vol. 33. No. 1—1997

### 1 Editor's Note—*Matthew V. Rudorfer*

### 3 Standardized Assessment of Dysthymia: Report of a National Institute of Mental Health Conference—*Harry E. Gwirtsman, Mary C. Blehar, James P. McCullough, James H. Kocsis, and Robert F. Prien*

### Assessment Measures for Clinical Studies

#### 13 Endicott Work Productivity Scale (EWPS): A New Measure to Assess Treatment Effects—*Jean Endicott and John Nee*

#### 17 A Severity Rating Scale for Body Dysmorphic Disorder: Development, Reliability, and Validity of a Modified Version of the Yale-Brown Obsessive Compulsive Scale—*Katharine A. Phillips, Eric Hollander, Steven A. Rasmussen, Bonnie R. Aronowitz, Concetta DeCaria, and Wayne K. Goodman*

#### 23 Preliminary Longitudinal Assessment of Quality of Life in Patients With Major Depression—*Jeffrey M. Pyne, Thomas L. Patterson, Robert M. Kaplan, Sandy Ho, J. Christian Gillin, Shahrokh Golshan, and Igor Grant*

### Methodological Issues in Psychopharmacological Research

#### 31 Growing Placebo Response Rate: The Problem in Recent Therapeutic Trials?—*E.H. Uhlenhuth, William Matuzas, Teddy D. Warner, and Peter M. Thompson*

#### 41 Factors That Influence the Outcome of Placebo- Controlled Antidepressant Clinical Trials—*I.A. Niklson, P.-E. Reimetz, and C. Sennet*

#### 53 Interrater Reliability Issues in Multicenter Trials, Part I: Theoretical Concepts and Operational Procedures Used in Department of Veterans Affairs Cooperative Study #394—*Kathlene Tracy, Lenard A. Adler, John Rotrosen, Robert Edson, Philip Lavori, and the Veterans Affairs Cooperative Study #394 Study Group*

#### 59 Interrater Reliability Issues in Multicenter Trials, Part II: Statistical Procedures Used in Department of Veterans Affairs Cooperative Study #394— *Robert Edson, Philip Lavori, Kathlene Tracy, Lenard A. Adler, John Rotrosen, and the Veterans Affairs Cooperative Study #394 Study Group*

#### 69 A Comparison of Patients With Major Depressive Disorder Recruited Through Newspaper Advertising Versus Consultation Referrals for Clinical Drug Trials—*Carol A. Miller, Cynthia L. Hooper, and David Bakish*

#### 75 Therapeutic Trial Participants: Where Do We Find Them and What Does It Cost?—*Robert J. Bielski and R. Bruce Lydiard*

### Treatment Issues in Clinical Psychopharmacology

#### 79 Clinical and Psychopharmacologic Practice Patterns of Psychiatrists in Routine Practice—*Joyce C. West, Deborah A. Zarin, and Harold Alan Pincus*

#### 87 Compliance With Maintenance Treatment in Bipolar Disorder—*Paul E. Keck Jr., Susan L. McElroy, Stephen M. Strakowski, Michelle L. Bourne, and Scott A. West*

#### 93 Economic Evaluation of Paroxetine and Imipramine in Depressed Outpatients—*Sarah T. Melton, Cynthia K. Kirkwood, Travain W. Farrar, Douglas D. Brink, and Norman V. Carroll*

#### 101 A Preliminary Study on the Efficacy of Sertraline and Imipramine on Anger Attacks in Atypical Depression and Dysthymia—*Maurizio Fava, Andrew A. Nierenberg, Frederic M. Quitkin, Sidney Zisook, Teri Pearlstein, Andrea Stone, and Jerrold F. Rosenbaum*

- 105** Anger Attacks and Treatment Nonadherence in a Perinatal Psychiatry Clinic—*Oommen Mammen, Katherine Shear, Catherine Greeno, Susan Wheeler, and Carolyn Hughes*

### Psychopharmacology in Geriatric Populations

- 109** Plasma Levels of Citalopram Enantiomers and Metabolites in Elderly Patients—*John P. Foglia, Bruce G. Pollock, Margaret A. Kirshner, Jules Rosen, Robert Sweet, and Benoit Mulsant*
- 113** Treatment of Elderly Institutionalized Bipolar Patients With Clozapine—*Richard W. Shulman, Anu Singh, and Kenneth I. Shulman*
- 119** Symptom Change and Extrapyrimal Side Effects During Acute Haloperidol Treatment in Chronic Geriatric Schizophrenics—*James J. Weisbard, Moris Pardo, and Simcha Pollack*
- 123** Memory, Language, and Praxis in Alzheimer's Disease: Norms for Outpatient Clinical Trial Populations—*P.M. Doraiswamy, F. Bieber, L. Kaiser, K. Connors, K.R. Krishnan, J. Reuning-Scherer, and B. Gulanski*
- 129** Dementia Drug Development: Use of Information Systems to Harmonize Global Drug Development—*Peter J. Whitehouse, Christine G. Sciuilli, and Robert M. Mason*

### Psychopharmacology in Children and Adolescents

- 135** Toward Clinically Relevant Clinical Trials—*L. Eugene Arnold, Kimberly Hoagwood, Peter S. Jensen, and Benedetto Vitiello*

- 143** Methylphenidate Patterns Among Medicaid Youths—*Julie Magno Zito, Daniel J. Safer, Susan dosReis, Laurence S. Magder, and Mark A. Riddle*

- 149** Venlafaxine in the Treatment of Children and Adolescents With Major Depression—*Miguel W. Mandoki, Maria R. Tapia, Maria A. Tapia, Gayla S. Sumner, and Janet L. Parker*

- 155** An Open Clinical Trial of Risperidone Monotherapy in Young Children With Autistic Disorder—*Robert L. Findling, Kathleen Maxwell, and Max Wiznitzer*

- 161** The Use of Prn and Stat Medication in Three Child Psychiatric Inpatient Settings—*Stuart L. Kaplan and Joan Busner*

### Drug/Alcohol Abuse

- 165** Double-Blind Fluoxetine in Depressed Alcoholic Smokers—*Jack R. Cornelius, Ihsan M. Salloum, Joan G. Ehler, Patricia J. Jarrett, Marie D. Cornelius, Ann Black, James M. Perel, and Michael E. Thase*
- 171** Carbohydrate-Deficient Transferrin: An Investigative Biochemical Marker of Heavy Alcohol Consumption—*Richard S. Saini, Helen M. Pettinati, Ann E. Semwanga, and Charles P. O'Brien*
- 177** Substance Abuse as a Risk Factor for Tardive Dyskinesia: A Retrospective Analysis of 1,027 Patients—*LaGenia Bailey, Sarz Maxwell, and Melanie M. Brandabur*

## Vol. 33, No. 2—1997

## Endocrinology and Psychopharmacology: Hormone-Treatment Interactions

**183** Editor's Note—*Matthew V. Rudorfer*

### I. Endocrine Factors in the Pathophysiology of Mental Disorders

**185** Persistent Changes in Corticotropin-Releasing Factor Systems Due to Early Life Stress: Relationship to the Pathophysiology of Major Depression and Post-Traumatic Stress Disorder—*Christine Heim, Michael J. Owens, Paul M. Plotsky, and Charles B. Nemeroff*

**193** A View on Noradrenergic, Hypothalamic-Pituitary-Adrenal Axis and Extrahypothalamic Corticotrophin-Releasing Factor Function in Anxiety and Affective Disorders: The Reduced Growth Hormone Response to Clonidine—*Jeremy D. Coplan, Daniel S. Pine, Laszlo A. Papp, and Jack M. Gorman*

**205** The Thyroid Axis and Mood Disorders: Overview and Future Prospects—*Sharon Esposito, Arthur J. Prange, Jr., and Robert N. Golden*

**219** Neuroregulatory Role of Gonadal Steroids in Humans—*Peter J. Schmidt and David R. Rubinow*

**221** Gender, Estrogen, and Schizophrenia—*Laurie A. Lindamer, James B. Lohr, M. Jackuelyn Harris, and Dilip V. Jeste*

**229** The Influence of Estrogen on Monoamine Oxidase Activity—*Sudeep G. Chakravorty and Uriel Halbreich*

### II. The Endocrine—Treatment Interface

**235** Gender Differences in Psychotropic Drug Metabolism—*Bruce G. Pollock*

**243** Effects of the Postpartum Period on Nortriptyline Pharmacokinetics—*Katherine L. Wisner, James M. Perel, Kathleen S. Peindl, Robert L. Findling, and Barbara H. Hanusa*

**249** Nortriptyline and Its Hydroxymetabolites in Breastfeeding Mothers and Newborns—*Katherine L. Wisner, James M. Perel, Robert L. Findling, and Robert L. Hinnes*

**253** Acute Alpha<sub>2</sub> Blockade by Idazoxan Increases Insulin and Lowers Plasma Glucose During Positron Emission Tomography—*Mark E. Schmidt, David S. Goldstein, Jennifer L. Schouten, John A. Matochik, Hyung-Gun Kim, and William Z. Potter*

**261** Sertraline in Coexisting Major Depression and Diabetes Mellitus—*Paul J. Goodnick, Adarsh Kumar, Joseph H. Henry, Virginia M.V. Buki, and Ronald B. Goldberg*

**265** Neuroendocrine Effects of Electroconvulsive Therapy (ECT)—*Conrad M. Swartz*

**273** Use of Thyroid Hormone to Diminish the Cognitive Side Effects of Psychiatric Treatment—*Geoffrey Tremont and Robert A. Stern*

### III. Hormones as Treatments

**281** Hormonal Interventions With Psychopharmacological Potential: An Overview—*Uriel Halbreich*

**287** Estrogen in Geriatric Psychopharmacology—*Barry D. Lebowitz, Bruce G. Pollock, and Lon S. Schneider*

**289** The Role of Estrogen in Late-Life Depression: Opportunities and Barriers to Research—*Barnett S. Meyers and Margaret L. Moline*

**293** Androgens in the Elderly: Will Androgen Replacement Therapy Improve Mood, Cognition, and Quality of Life in Aging Men and Women—*Mary F. Morrison*

**297** Progesterone: Does It Affect Response to Drug?—*Patricia D. Kroboth and James W. McAuley*

**303** Gonadotropin-Releasing Hormone Agonist in the Treatment of Premenstrual Symptoms With and Without Ongoing Dysphoria: A Controlled Study—*Ellen W. Freeman, Steven J. Sondheimer, and Karl Rickels*

**311** Anxiety and Mood Disorders Associated With Gonadotropin-Releasing Hormone Agonist Therapy—*Julia K. Warnock and J. Clark Bundren*

## Vol. 33. No. 3—1997

**Research Priorities in Eating Disorders**

- 317** **Editors' Note**—*Matthew V. Rudorfer and Harold Goldstein*

**I. Workshop Report**

- 321** Report of the National Institutes of Health (NIH) Workshop on the Development of Research Priorities in Eating Disorders—*Carlos M. Grilo, Michael J. Devlin, Fary M. Cachelin, and Susan Z. Yanovski*

**II. Neurobiology and Genetics**

- 335** Anorexia Nervosa, Obsessional Behavior, and Serotonin—*Walter H. Kaye*
- 345** Research Update on Serotonin Function in Bulimia Nervosa and Anorexia Nervosa—*Barbara E. Wolfe, Eran D. Metzger, and David C. Jimerson*
- 355** Behavior Genetics and Eating Disorders—*John K. Hewitt*
- 359** Issues in Mapping Genes for Eating Disorders—*David B. Allison and Myles S. Faith*

**III. Clinical Issues**

- 369** Diagnostic Criteria for Eating Disorders: Current Concerns and Future Directions—*B. Timothy Walsh and Caroline B. Kahn*
- 373** Eating Behavior and Eating Disorders: The Interface Between Clinical Research and Clinical Practice—*Suzanne R. Sunday and Katherine A. Halmi*
- 381** Eating Disorders and Comorbidity: Empirical, Conceptual, and Clinical Implications—*Stephen A. Wonderlich and James E. Mitchell*

- 391** Males With Eating Disorders: Challenges for Treatment and Research—*Arnold E. Andersen and John E. Holman*

- 399** Mechanisms and Treatment Options for Bone Loss in Anorexia Nervosa—*Steven Grinspoon, David Herzog, and Anne Klibanski*

**IV. Prevention Research**

- 405** The Future of Risk Factor Research in Understanding the Etiology of Eating Disorders—*Gloria R. Leon, Pamela K. Keel, Kelly L. Klump, and Jayne A. Fulkerson*
- 413** Priorities in Prevention Research for Eating Disorders—*C. Barr Taylor and Tamara Altman*
- 419** Prevention of Eating Disorders: Directions for Future Research—*Niva Piran*

**V. Treatment Research**

- 425** Does Adjunctive Fluoxetine Influence the Post-Hospital Course of Restrictor-Type Anorexia Nervosa? A 24-Month Prospective, Longitudinal Followup and Comparison With Historical Controls—*Michael Strober, Roberta Freeman, Mark DeAntonio, Carlyn Lampert, and Jane Diamond*
- 433** Pharmacotherapy of Bulimia Nervosa and Binge Eating Disorder: Longer-Term Outcomes—*W. Stewart Agras*
- 437** Psychological Treatment of Bulimia Nervosa and Binge Eating Disorder—*Denise E. Wilfley and Lisa R. Cohen*

**VI. Appendix**

- 455** NIMH Eating Disorders Program Announcement

**1997 NCDEU Abstracts****465** Introduction**467** Free Communications**483** Poster Sessions**609** Author Index



## Vol. 33. No. 4—1997

**1997 NCDEU Selected Proceedings—Part I**

- 617** Editor's Note—*Matthew V. Rudorfer*

**TREATMENT GUIDELINE DEVELOPMENT**

- 619** Manual Development for the Treatment of Child and Adolescent Disorders—*Euthymia D. Hibbs, Gregory Clarke, Lily Hechtman, Howard B. Abikoff, Laurence L. Greenhill, and Peter S. Jensen*
- 631** Consensus Methods in Practice Guideline Development: A Review and Description of a New Method—*David A. Kahn, John P. Docherty, Daniel Carpenter, and Allen Frances*
- 641** Evidence-Based Practice Guidelines—*Deborah A. Zarin, Leslie Seigle, Harold Alan Pincus, and John S. McIntyre*

**DEPRESSION AND RELATED DISORDERS**

- 647** A Comparison of Placebo Response With Major Depressive Disorder in Patients Recruited Through Newspaper Advertising Versus Consultation Referrals—*Carol A. Miller, Cynthia L. Hooper, and David Bakish*
- 653** Measuring Outcomes and Costs for Major Depression—*Brenda M. Booth, Mingliang Zhang, Kathryn M. Rost, James A. Clardy, Leslie G. Smith, and G. Richard Smith*
- 659** Sertraline Does Not Inhibit Cytochrome P450 3A-Mediated Drug Metabolism *In Vivo*—*Sheldon H. Preskorn, Jeff Alderman, David J. Greenblatt, and W. Dale Horst*

- 667** Antidepressant Overdoses and Resultant Emergency Department Services: The Impact of SSRIs—*Steven C. Stoner, Patricia A. Marken, William A. Watson, Joy L. Switzer, Michael F. Barber, Vickie L. Meyer, Roger W. Sommi, Jr., and Mark T. Steele*

- 671** A Benefit-Risk Analysis of Once-Daily Venlafaxine Extended Release (XR) and Venlafaxine Immediate Release (IR) in Outpatients With Major Depression—*Richard Entsuah and Rohini Chitra*

- 677** The Cognitive, Subjective, and Physical Effects of a *Ginkgo biloba*/*Panax ginseng* Combination in Healthy Volunteers With Neurasthenic Complaints—*K.A. Wesnes, R.A. Faleni, N.R. Hefting, G. Hoogsteen, J.J.G. Houben, E. Jenkins, J.H.G. Jonkman, J. Leonard, O. Petrini, and J.J. van Lier*

**BIPOLAR DISORDER**

- 685** Intracellular Phosphatidylinositol Pathway Abnormalities in Bipolar Disorder Patients—*Jair C. Soares and Alan G. Mallinger*
- 693** Maintenance Clinical Trials in Bipolar Disorder: Design Implications of the Divalproex-Lithium-Placebo Study—*Charles L. Bowden, Alan C. Swann, Joseph R. Calabrese, Susan L. McElroy, David Morris, Frederick Petty, Robert M.A. Hirschfeld, and Laszlo Gyulai*

**GERIATRIC PSYCHOPHARMACOLOGY**

- 701** Outcomes for Antidepressant Trials in Late-Life Depression—*Barnett S. Meyers and Martha L. Bruce*

- 707** Characteristics of Fluoxetine Versus Placebo Responders in a Randomized Trial of Geriatric Depression—*Deborah L. Ackerman, Sander Greenland, Alexander Bystritsky, and Gary W. Small*

- 715** Low-Level Serum Anticholinergic as a Source of Baseline Cognitive Heterogeneity in Geriatric Depressed Patients—*Robert D. Nebes, Bruce G. Pollock, Benoit H. Mulsant, Margaret A. Kirshner, Edythe Halligan, Michelle Zmuda, and Charles F. Reynolds III*

- 721** Finding and Treating Depression in Alzheimer's Patients: A Study of the Effects on Patients and Caregivers—*Eric Pfeiffer, Dorothy Baxter, Elizabeth Candelora, Scott Haag, Lakshmi Nadiminti, and Paul Leaverton*

## SEXUAL FUNCTION

- 731** The Changes in Sexual Functioning Questionnaire (CSFQ): Development, Reliability, and Validity—*Anita H. Clayton, Elizabeth L. McGarvey, and Gail J. Clavet*
- 747** Comparison of Sexual Functioning in Clinical and Nonclinical Populations Using the Changes in Sexual Functioning Questionnaire (CSFQ)—*Anita H. Clayton, Elizabeth L. McGarvey, Gail J. Clavet, and Lisa Piazza*

- 755** Treatment-Emergent Changes in Sexual Function With Selective Serotonin Reuptake Inhibitors as Measured With the Rush Sexual Inventory—*John Zajecka, Sunny Mitchell, and Jan Fawcett*

- 761** Female Hypoactive Sexual Desire Disorder Due to Androgen Deficiency: Clinical and Psychometric Issues—*Julia "Jill" K. Warnock, J. Clark Bundren, and David W. Morris*

## PREMENSTRUAL DISORDERS

- 767** State and Trait Serotonergic Abnormalities in Women With Dysphoric Premenstrual Syndromes—*Elena M. Kouri and Uriel Halbreich*

- 771** Intermittent Fluoxetine Dosing in the Treatment of Women With Premenstrual Dysphoria—*Meir Steiner, Marilyn Korzekwa, John Lamont, and Annette Wilkins*

- 775** 1997 Cumulative Table of Contents

- 783** 1997 Cumulative Author Index

- 803** 1997 Cumulative Keyword Index



